Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4821.38% is 56% below its 3-year average of -3087.36%, around the middle of its 3-year range (-9207.10%–-978.94%).
5.13% above its 12-month average of -5081.99%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3025.57%.
EBITDA MARGIN
-4821.38%
EBITDA MARGIN AVG TTM
-5081.99%
EBITDA MARGIN AVG 3Y
-3263.06%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+5.13%
CURRENT VS 3Y AVG
-47.76%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Anteris Technologies Global Corp.
Market Cap
$734.10M
EBITDA Margin
-4821.38%
TTM Avg
-5081.99%
3Y Avg
-3263.06%
5Y Avg
N/A
Market Cap
$719.64M
EBITDA Margin
-414.93%
TTM Avg
-258.43%
3Y Avg
-185.54%
5Y Avg
-212.52%
Market Cap
$749.55M
EBITDA Margin
-27116.80%
TTM Avg
-23848.80%
3Y Avg
-16467.00%
5Y Avg
-16467.00%
Market Cap
$709.33M
EBITDA Margin
52.93%
TTM Avg
53.31%
3Y Avg
49.89%
5Y Avg
44.80%
Market Cap
$767.46M
EBITDA Margin
-123018.64%
TTM Avg
-69257.96%
3Y Avg
-35033.94%
5Y Avg
-23599.85%
Market Cap
$774.32M
EBITDA Margin
-4915.19%
TTM Avg
-4915.19%
3Y Avg
-4915.19%
5Y Avg
-4915.19%
Market Cap
$775.72M
EBITDA Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$776.24M
EBITDA Margin
-28.62%
TTM Avg
-126.34%
3Y Avg
-26187.68%
5Y Avg
-23869.36%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $734.10M | -4821.38% | -5081.99% | -3263.06% | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -414.93% | -258.43% | -185.54% | -212.52% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -27116.80% | -23848.80% | -16467.00% | -16467.00% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 52.93% | 53.31% | 49.89% | 44.80% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -123018.64% | -69257.96% | -35033.94% | -23599.85% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | -4915.19% | -4915.19% | -4915.19% | -4915.19% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Geron Corporation (GERN)vs › | $776.24M | -28.62% | -126.34% | -26187.68% | -23869.36% |
| Annexon, Inc. (ANNX)vs › | $688.14M | N/A | N/A | N/A | N/A |
Gross Margin
-16.6%
EBITDA Margin
-4821.4%
Operating Margin
-4908.2%
Net Margin
-4619.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3025.57% |
| 2026-03-31 | -4772.87% |
| 2025-12-31 | -9207.10% |
| 2025-09-30 | -5092.77% |
| 2025-06-30 | -3311.65% |
| 2025-03-31 | -3844.78% |
| 2024-12-31 | -3853.29% |
| 2024-09-30 | -2798.40% |
| 2024-06-30 | -2928.64% |
| 2024-03-31 | -2276.76% |
| 2023-12-31 | -2864.92% |
| 2023-09-30 | -1821.99% |
| 2023-06-30 | -2565.05% |
| 2023-03-31 | -978.94% |
